Success Metrics

Clinical Success Rate
70.0%

Based on 14 completed trials

Completion Rate
70%(14/20)
Active Trials
2(9%)
Results Posted
50%(7 trials)
Terminated
6(26%)

Phase Distribution

Ph not_applicable
1
4%
Ph phase_1
9
39%
Ph phase_2
10
43%
Ph phase_3
2
9%

Phase Distribution

9

Early Stage

10

Mid Stage

2

Late Stage

Phase Distribution22 total trials
Phase 1Safety & dosage
9(40.9%)
Phase 2Efficacy & side effects
10(45.5%)
Phase 3Large-scale testing
2(9.1%)
N/ANon-phased studies
1(4.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

70.0%

14 of 20 finished

Non-Completion Rate

30.0%

6 ended early

Currently Active

2

trials recruiting

Total Trials

23

all time

Status Distribution
Active(3)
Completed(14)
Terminated(6)

Detailed Status

Completed14
Terminated6
Not yet recruiting1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
23
Active
2
Success Rate
70.0%
Most Advanced
Phase 3

Trials by Phase

Phase 19 (40.9%)
Phase 210 (45.5%)
Phase 32 (9.1%)
N/A1 (4.5%)

Trials by Status

terminated626%
completed1461%
not_yet_recruiting14%
active_not_recruiting14%
recruiting14%

Recent Activity

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT04979052Phase 2

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

Active Not Recruiting
NCT06381661Phase 2

Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

Not Yet Recruiting
NCT06529731Phase 2

Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
NCT03747484Phase 1

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Terminated
NCT02666768Phase 2

ACTIMMUNE in Intermediate Osteopetrosis

Completed
NCT01468337Phase 1

Topical Interferon Gamma-1b for Central Serous Chorioretinopathy

Completed
NCT03063632Phase 2

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

Completed
NCT00001112Phase 1

The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine

Completed
NCT00001004Phase 2

A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients With AIDS Related Complex

Completed
NCT00000761Phase 1

Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children

Completed
NCT01965327Phase 2

Interferon Gamma-1b in Friedreich Ataxia (FRDA)

Completed
NCT03548818

Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease

Completed
NCT02338973Phase 1

Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)

Terminated
NCT01376362Phase 1

Topical Interferon Gamma for Macular Edema Secondary to Uveitis

Completed
NCT00012467Phase 2

Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

Completed
NCT00076635Phase 3

An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF

Terminated
NCT00043303Phase 2

Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis

Completed
NCT00043342Phase 1

Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis

Completed
NCT00057447Phase 1

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

Terminated
NCT00043316Phase 1

Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis

Completed

Drug Details

Intervention Type
DRUG
Total Trials
23